LAVA Therapeutics N.V. (LVTX)
NL — Healthcare Sector
Automate Your Wheel Strategy on LVTX
With Tiblio's Option Bot, you can configure your own wheel strategy including LVTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LVTX
- Rev/Share 0.1856
- Book/Share 0.9588
- PB 1.382
- Debt/Equity 0.0121
- CurrentRatio 6.7316
- ROIC -0.4596
- MktCap 34854523.0
- FreeCF/Share -0.6105
- PFCF -2.1231
- PE -1.2708
- Debt/Assets 0.0044
- DivYield 0
- ROE -0.8668
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LVTX | Leerink Partners | Outperform | Market Perform | $11 | $2 | Dec. 12, 2024 |
| Downgrade | LVTX | JMP Securities | Mkt Outperform | Market Perform | -- | -- | Dec. 11, 2024 |
News
About LAVA Therapeutics N.V. (LVTX)
- IPO Date 2021-03-26
- Website https://www.lavatherapeutics.com
- Industry Biotechnology
- CEO Mr. Stephen Allen Hurly M.B.A., M.Sc.
- Employees 34
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.